Table 2.
Patients' characteristics and HBOT effect according to indication.
| Characteristic | pCD | ECF | PG | P |
|---|---|---|---|---|
| Age (at CD onset) | ||||
| Mean ± SD (years) | 27.8 ± 10.1 | 26.1 ± 6.5 | 29.1 ± 9.2 | 0.87∗ |
| Age (at HBOT) | ||||
| Mean ± SD (years) | 38.3 ± 13.7 | 37.2 ± 11.1 | 41.0 ± 12.8 | 0.83∗ |
| CD duration | ||||
| Mean ± SD (years) | 10.5 ± 6.2 | 11.8 ± 5.7 | 11.8 ± 3.1 | 0.95∗ |
| Duration of anti-TNF therapy | ||||
| Mean ± SD (months) | 42.8 ± 21.6 | 43.6 ± 16.8 | 36.1 ± 11.5 | 0.81∗ |
| Number of HBOT sessions | ||||
| Mean ± SD | 29.9 ± 15.0 | 30.8 ± 21.5 | 29.3 ± 12.7 | 0.98∗ |
| Complete healing rate | ||||
| N (%) | 20 (80.0) | 11 (84.6) | 6 (100.0) | 0.38∗∗ |
pCD: perineal fistulizing Crohn's disease; ECF: enterocutaneous fistula; PG: pyoderma gangrenosum; CD: Crohn's disease; SD: standard deviation; HBOT: hyperbaric oxygen therapy. ∗ANOVA test. ∗∗Pearson chi-square test.